scholarly journals Circulating resistin and follistatin levels in obese and non-obese women with polycystic ovary syndrome: A systematic review and meta-analysis

PLoS ONE ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. e0246200
Author(s):  
Tahereh Raeisi ◽  
Hossein Rezaie ◽  
Mina Darand ◽  
Akram Taheri ◽  
Nazila Garousi ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Meta Analysis ◽  
Significant Heterogeneity ◽  
Obese Women ◽  
Ovary Syndrome ◽  
Obesity Status ◽  
Significant Difference ◽  
Mean Differences ◽  
Stratified Analysis

This meta-analysis was performed to resolve the inconsistencies regarding resistin and follistatin levels in women with polycystic ovary syndrome (PCOS) by pooling the available evidence. A systematic literature search using PubMed and Scopus was carried out through November 2020 to obtain all pertinent studies. Weighted mean differences (WMDs) with corresponding 95% confidence intervals (CIs) were calculated to evaluate the strength of the association between the levels of resistin and follistatin with PCOS in the overall and stratified analysis by obesity status. A total of 47 publications, 38 for resistin (2424 cases; 1906 controls) and 9 studies for follistatin (815 cases; 328 controls), were included in the meta-analysis. Resistin levels were significantly higher in PCOS women compared with non-PCOS controls (WMD = 1.96 ng/ml; 95%CI = 1.25–2.67, P≤0.001) as well as in obese PCOS women vs. obese controls, and in non-obese PCOS women compared with non-obese controls, but not in obese PCOS vs. non-obese PCOS patients,. A significantly increased circulating follistatin was found in PCOS patients compared with the controls (WMD = 0.44 ng/ml; 95%CI = 0.30–0.58, P≤0.001) and in non-obese PCOS women compared with non-obese controls and in obese PCOS women vs. obese controls, but, no significant difference in follistatin level was observed in obese PCOS compared with non-obese PCOS women. Significant heterogeneity and publication bias was evident for some analyses. Circulating levels of resistin and follistatin, independent of obesity status, are higher in women with PCOS compared with controls, showing that these adipokines may contribute to the pathology of PCOS.

scholarly journals Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis

2019 ◽  
Vol 111 (1) ◽  
pp. 168-177 ◽  
Author(s):  
Shiqin Zhu ◽  
Bingqian Zhang ◽  
Xiao Jiang ◽  
Zeyan Li ◽  
Shigang Zhao ◽  
...  
Keyword(s):  
Systematic Review ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Meta Analysis ◽  
Obese Women ◽  
Metabolic Disturbances ◽  
Ovary Syndrome

scholarly journals Association between Insulin Resistance and Cardiovascular Risk Factors in Polycystic Ovary Syndrome Patients

2018 ◽  
Vol 40 (04) ◽  
pp. 188-195 ◽  
Author(s):  
Miriam Wanderley ◽  
Lara Pereira ◽  
Carla Santos ◽  
Vinícius Cunha ◽  
Mariam Neves
Keyword(s):  
Insulin Resistance ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Normal Body Mass Index ◽  
Fisher Exact Test ◽  
Model Assessment ◽  
Obese Women ◽  
Ovary Syndrome ◽  
Indirect Methods ◽  
Significant Difference

Objective To analyze the association between the indirect methods of evaluating insulin resistance (IR) and blood pressure, anthropometric and biochemical parameters in a population of polycystic ovary syndrome (PCOS) patients. Methods Cross-sectional study performed at the Hospital Universitário de Brasília (HUB, in the Portuguese acronym) involving PCOS patients diagnosed from January 2011 to January 2013. Four indirect methods, namely, fasting blood insulin level, fasting glucose/insulin ratio (G/I), homeostatic model-assessment-insulin resistance (HOMA-IR), and the quantitative insulin sensitivity check index (QUICKI), were used to obtain the IR diagnosis. The data were analyzed using the test of proportions, the Chi-square test, and Fisher exact test, when indicated. Results Out of the 83 patients assessed, aged 28.79 ± 5.85, IR was found in 51.81–66.2% of them using the G/I ratio and the QUICKI, respectively. The test of proportions did not show a significant difference between the methods analyzed. The proportion of IR diagnoses was statistically higher in obese women than in women with normal body mass index (BMI). We observed a statistically significant association between all the methods for diagnosing IR and BMI, waist circumference (WC) and lipid accumulation product (LAP). With regards to arterial hypertension (AH), we observed a significant association according to three methods, with the exception of the ratio G/I. Conclusion Insulin resistance prevalence varied according to the diagnostic method employed, with no statistical difference between them. The proportion of IR diagnoses was statistically higher in obese women than in women with normal BMI. We observed a significant association between IR and WC, BMI, LAP, as well as dyslipidemia and AH in a high proportion of patients.

scholarly journals Prostatic-specific antigen (PSA) levels in patients with polycystic ovary syndrome (PCOS): a meta-analysis

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Zeng-Hong Wu ◽  
Yun Tang ◽  
Xun Niu ◽  
Fei-Fei Pu ◽  
Xi-Yue Xiao ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Meta Analysis ◽  
Specific Antigen ◽  
Significant Heterogeneity ◽  
Prostatic Specific Antigen ◽  
Ovary Syndrome ◽  
Searching Strategy ◽  
Reproductive Endocrine

Abstract Purpose The polycystic ovary syndrome (PCOS) is a reproductive endocrine disorder, clinically characterized by oligo-ovulation/chronic anovulation, menstrual irregularities, hyperandrogenism (such as hirsutism, acne), hyperinsulinemia, and obesity. Prostatic-specific antigen (PSA) has been identified as a potential new marker in PCOS women. Although the precise role of PSA in PCOS patients still remains undetermined, PSA might serve as a useful clinical marker and might even represent a new diagnostic criterion of hyperandrogenemia in females of PCOS. Methods A meta-analysis was performed in the study to identify the association between the polycystic ovary syndrome and prostatic-specific antigen. To identify eligible original articles, we searched a range of computerized databases, including Medline via PubMed, EMBASE, CNKI and Web of Science with a systematic searching strategy. The characteristics of each study and standard mean differences (SMD) with corresponding confidence intervals (CIs) were calculated and subgroup analysis was performed to analyze heterogeneity. Results A total of 532 patients from seven articles were included in the meta-analysis. We identified a significant relationship between polycystic ovary syndrome and prostatic-specific antigen, with a pooled SMD of 0.81 (95% CI: 0.58 to 1.04; P < 0.01). The pooled data were calculated with the random-effects model as a moderate significant heterogeneity was found among the studies. Conclusions The meta-analysis suggested that there was a significant association between the polycystic ovary syndrome and prostatic-specific antigen and we should not ignore the role of PSA in the PCOS patients in clinical.

scholarly journals The Effects of Salvia miltiorrhiza on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 2021 ◽  
pp. 1-12
Author(s):  
Wenjuan Shen ◽  
Bao Jin ◽  
Yaguang Han ◽  
Hongwei Wang ◽  
Huan Jiang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Salvia Miltiorrhiza ◽  
Meta Analysis ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Cochrane Library ◽  
Ovary Syndrome ◽  
Significant Difference

Objective. Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. As a traditional medicine, Salvia miltiorrhiza (S. miltiorrhiza) has been widely used in the treatment of many gynecological diseases, but the efficacy of S. miltiorrhiza in women with PCOS has not been assessed. The purpose of this systematic review and meta-analysis was to evaluate the effectiveness and safety of S. miltiorrhiza in women with PCOS. Methods. We conducted searches in PubMed, Embase, the Cochrane Library, the China National Knowledge Infrastructure, the Wanfang Database, the Chinese Scientific Journal Database, and the Chinese BioMedical database from inception to December 23, 2020, to identify studies that met the inclusion criteria. The quality of the evidence was estimated using the Cochrane Reviewer Handbook 5.0.0, and the meta-analysis was performed using RevMan 5.3.5 software. Results. Six randomized controlled trials (RCTs) involving 390 patients with PCOS were included. The studies suggested that S. miltiorrhiza extract combined with letrozole (LET) was more effective in improving pregnancy rate (RR: 2.60, 95% CI: 1.06 to 6.39, P = 0.04 ) compared to LET alone. S. miltiorrhiza extract was associated with decreased fasting blood glucose (MD: –0.25, 95% CI: –0.37 to –0.13, P < 0.0001 ), fasting insulin (MD: –1.16, 95% CI: –1.74 to –0.58, P < 0.0001 ), total cholesterol (TC) (MD: –0.58, 95% CI: –0.72 to –0.43, P < 0.00001 ), and triglycerides (TG) (MD: –0.31, 95% CI: –0.35 to –0.26, P < 0.00001 ) compared with placebo, but not with improvements in body mass index or waist-to-hip ratio (MD: –1.41, 95% CI: –4.81 to 2.00, P = 0.42 ; MD: –0.02, 95% CI: –0.05 to 0.01, P = 0.16 , respectively). There was a significant difference between S. miltiorrhiza extract combined with cyproterone acetate (CPA) and CPA alone in terms of decreasing TC (MD: –0.77, 95% CI: –0.89 to –0.65, P < 0.00001 ), TG (MD: –0.43, 95% CI: –0.65 to –0.20, P < 0.0001 ), and low-density lipoprotein cholesterol (MD: –0.49, 95% CI: –0.66 to –0.33, P < 0.00001 ) and increasing high-density lipoprotein cholesterol (MD: 0.30, 95% CI: 0.20, 0.40, P < 0.00001 ). In addition, S. miltiorrhiza extract also decreased testosterone, follicle-stimulating hormone, and luteinizing hormone. The studies did not mention any adverse events with S. miltiorrhiza extract. Conclusion. The current studies indicate that S. miltiorrhiza has beneficial effects on reproduction and glucose and lipid metabolism in patients with PCOS, and it is generally safe for clinical application. However, more prospective RCTs with large samples, multiple centers, and longer intervention duration are needed in the future to obtain more reliable conclusions.

scholarly journals Comparison of the umbilical cord Blood’s anti-Mullerian hormone level in the newborns of mothers with polycystic ovary syndrome (PCOS) and healthy mothers

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Faezeh Tadaion Far ◽  
Shahideh Jahanian Sadatmahalleh ◽  
Saeideh Ziaei ◽  
Anoshirvan Kazemnejad
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Cord Blood ◽  
Pregnant Women ◽  
Umbilical Cord ◽  
Polycystic Ovary ◽  
Clinical Findings ◽  
Control Group ◽  
Obese Women ◽  
Ovary Syndrome ◽  
Significant Difference

Abstract Background Polycystic ovary syndrome (PCOS) is one of the most common endocrine diseases. At present, the cause of the disease is not fully understood, but many studies have shown that PCOS is associated with genetic and environmental factors. The present study aimed to assess the umbilical cord blood’s Anti-mullerian hormone (AMH) level in the newborns of mothers suffering from PCOS comparing to healthy mothers. Methods This prospective cohort study was conducted on 120 pregnant women with PCOS, who were selected through Rotterdam criteria, and 60 healthy pregnant women as the control group. The subjects in each group were divided into obese and non-obese mothers according to their body mass index (BMI) before pregnancy. The cord blood samples were collected from the offsprings on the time of childbirth. Finally, the circulating concentrations of AMH in both sexes of the newborns were determined by specific assays. Results The research results showed that the blood level of AMH was higher in the neonates of obese mothers with PCOS comparing to the controls (P < 0.001). Mean AMH level was higher in male neonates born from non-obese PCOS mothers than in the controls (P < 0.001); however, there was not a significant difference in the level of AMH in female neonates between these two groups (P = 0.264). Also the level of the above biomarker was higher in both sexes of the neonates belonging to obese PCOS mothers compared with the neonates born from non-obese PCOS mothers (P < 0.001). Conclusion(s) It can be said that the cord blood AMH level of neonates from obese women with PCOS is higher than that in the newborns of non-obese PCOS mothers. Further longitudinal studies are needed to confirm the clinical findings of the present research.

scholarly journals Prevalence of Asthma in Polycystic Ovary Syndrome Women: A Meta-analysis

2020 ◽  
Author(s):  
Honghao Sun ◽  
Da Li ◽  
Jiao Jiao ◽  
Qing Liu ◽  
Jiansu Bian ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Random Effects ◽  
Study Design ◽  
Polycystic Ovary ◽  
Meta Analysis ◽  
Random Effects Model ◽  
China National Knowledge Infrastructure ◽  
Ovary Syndrome ◽  
Increased Risk ◽  
Significant Difference

Abstract Background: A few publications have reported the prevalence of asthma in polycystic ovary syndrome (PCOS) patients. But it remains debatable whether PCOS is an independent risk factor of asthma. Thus we carried out this systematic review and meta-analysis to assess the association between PCOS and asthma.Methods：PubMed, Embase, web of science, Scopus, Cochrane trial register, China National Knowledge Infrastructure (CNKI) and Wanfang Databases were searched for studies published from inception to October 2020. We extracted the data and performed the meta-analysis under the guidance of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We used a random-effects model and calculated the odds ratios (ORs) and 95% confidence intervals (95% CIs).Results：A total of 6 articles concerning 26876 PCOS women and 156143 healthy controls were included. According to the result of the study, PCOS patients have increased risk of asthma (OR=1.75, 95%CI=1.40–2.19, I2=91.2%, P=0.000, random-effects model). When stratified by region, diagnostic cirteria for asthma and study design, the results did not show significant difference.Conclusions： PCOS leads to higher asthma risk, and this association is independent to region, diagnostic cirteria for asthma and study design.

scholarly journals Effect of a low-starch/low-dairy diet on fat oxidation in overweight and obese women with polycystic ovary syndrome

2014 ◽  
Vol 39 (11) ◽  
pp. 1237-1244 ◽  
Author(s):  
Ali M. Pohlmeier ◽  
Jennifer L. Phy ◽  
Phillip Watkins ◽  
Mallory Boylan ◽  
Julian Spallholz ◽  
...  
Keyword(s):  
Body Weight ◽  
Polycystic Ovary Syndrome ◽  
Dietary Intervention ◽  
Polycystic Ovary ◽  
Fat Oxidation ◽  
Carbohydrate Oxidation ◽  
Obese Women ◽  
Ovary Syndrome ◽  
Increased Risk ◽  
Significant Difference

Polycystic ovary syndrome (PCOS) affects between 4%–18% of reproductive-aged women and is associated with increased risk of obesity and obesity-related disease. PCOS is associated with hyperinsulinemia, which is known to impair fat oxidation. Research shows that carbohydrates from dairy and starch-based foods cause greater postprandial insulin secretion than carbohydrates from nonstarchy vegetables and fruits. The purpose of this study was to determine whether an ad libitum 8-week low-starch/low-dairy diet would improve fasting and postprandial fat oxidation after a high saturated fat liquid meal (HSFLM) in overweight and obese women with PCOS. Prospective 8-week dietary intervention using a low-starch/low-dairy diet in 10 women (body mass index ≥25 kg/m2 and ≤45 kg/m2) with PCOS. Indirect calorimetry was used at fasting and for 5 h following consumption of the HSFLM to determine respiratory exchange ratio (RER), macronutrient oxidation, and energy expenditure (EE) at week 0 and week 8. Participants had a reduction in body weight (–8.1 ± 1.8 kg, p < 0.05) and fasting insulin (–19.5 ± 8.9 μg/mL, p < 0.05) after dietary intervention; however, these were not significantly correlated with improved fat oxidation. There was a reduction in fasting RER, and fasting and postprandial carbohydrate oxidation, and an increase in fasting and postprandial fat oxidation after adjusting for body weight. There was also significant difference in incremental area under the curve from pre- to post-diet for fat (0.06 ± 0.00 g/kg per 5 h; p < 0.001) and carbohydrate oxidation (–0.29 ± 0.06 g/kg per 5 h; p < 0.001), but not for RER or EE. In conclusion, an 8-week low-starch/low-dairy diet increased fat oxidation in overweight and obese women with PCOS.

Sign in / Sign up

Export Citation Format

Share Document